Press

R&A PSYINS Announces Strategic Partnership with Nucleus to Provide the Psychedelic Industry Insurance Coverage

Mar 16 • 3 min read

R&A PSYINS, an independent insurance broker that provides necessary insurance coverages to the psychedelic medicinal industry, today announced a strategic partnership with Nucleus Holding, Inc. “(Nucleus”), a venture studio which owns and operates a portfolio of companies that connects stakeholders within the psychedelics industry. This landmark partnership was established to address a paramount issue facing psychedelic medicinal…

Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia

Mar 15 • 2 min read

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has achieved positive results for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. The study results evaluated the feasibility of using a rising dose design or maximum feasibility. In…

Field Trip Health & Wellness to Close Clinics in 5 Locations

Mar 15 • 2 min read

Field Trip Health & Wellness Ltd. (TSX-V: FTHW) today announced that, in an effort to reduce expenditures and preserve capital, it will be closing the Field Trip Health Centres located in Chicago, Washington DC, Seattle, San Diego and Fredericton. The anticipated last day of operation for each of these locations will be on or around…

Filament Health Announces FDA Approval of Phase II Clinical Trial Studying Psilocybin for Methamphetamine Use Disorder

Mar 15 • 2 min read

Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical–stage natural psychedelic drug development company, today announced approval from the United States Food and Drug Administration (FDA) for a clinical trial at the University of California San Francisco’s Translational Psychedelic Research Program (TrPR). The investigator initiated trial will study the effects of PEX010, Filament’s botanical…

BetterLife Closes $1,857,143 of Private Placement

Mar 15 • 3 min read

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce the closing of its brokered private placement offering pursuant to which the Company issued 15,000,000 units of the Company (“Units”) at a price of $0.10 per Unit for aggregate gross…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441